AAS ›› 2014, Vol. 45 ›› Issue (6): 779-784.doi: 10.3969/j.issn.0529-1356.2014.06.009

Previous Articles     Next Articles

Expression and significance of arrestin beta 1 in patients with glioma

WEN Pu-shuai 1*GAO Jing2 LI Wen-hui3 XI Huan-jiu3   

  1. 1. Department of Pathophysiology, Liaoning Medical University; 2. Department of Pathology, the First Affiliated Hospital of Liaoning Medical University; 3. Department of Anatomy, Liaoning Medical University; Liaoning Jinzhou 121001, China
  • Received:2014-02-27 Revised:2014-03-27 Online:2012-12-06 Published:2014-12-06
  • Contact: WEN Pu-shuai E-mail:wenpushuai@163.com

Abstract:

Objective To detect the expression levels of arrestin beta 1 (ARRB1) in patients with glioma, and assess its clinical significance. Methods The expression levels of ARRB1 in glioma cell lines were detected by RT-PCR and Western blot; ARRB1 mRNA expression in glioma was analyzed from Oncomine database and Project Betastasis platform; the expression of ARRB1 in glioma and peritumoral brain tissue was detected by immunohistochemistry; the association of ARRB1 expression levels with the prognosis of patients was analyzed by Kaplan Meier method. Results Compared with normal brain tissue and cell line HEK293, the mRNA and protein levels of ARRB1 in glioma cell lines were reduced; Oncomine database showed ARRB1 mRNA levels in multiple glioma microarray were significantly lower than the normal control group (P<0.001), specially in highly malignant glioblastoma. Immunohistochemistry data showed that ARRB1 expression in glioma tissues was reduced compared with the peritumoral brain tissue, and the expression of ARRB1 in Ⅲ-Ⅳ stage of gliomas was reduced more significantly than that in stage Ⅰ-Ⅱ glioma. In addition, Kaplan-Meier survival curves showed that the expression level of ARRB1 in glioma was correlated with patients survival (P<0.05). Conclusion Reduced ARRB1 expression level in glioma could be used to evaluate the clinical and pathological features of glioma, and the ARRB1 can be used a biomarker to judge the prognosis of patients with glioma.

Key words: Glioma, Arrestin beta 1, Prognosis, Immunohistochemistry, Human